Kenneth R. Carson
Advanced in Progressive Multifocal Leukoencephalopathy

Dr. Kenneth R. Carson

Hematology | Oncology
675 N St Clair St Ste 21-100, Galter Pavilion, 
Chicago, IL 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
25 Years of Experience
Advanced in Progressive Multifocal Leukoencephalopathy
675 N St Clair St Ste 21-100, Galter Pavilion, 
Chicago, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Kenneth Carson is a Hematologist and an Oncologist in Chicago, Illinois. Dr. Carson has been practicing medicine for over 25 years and is rated as an Advanced provider by MediFind in the treatment of Progressive Multifocal Leukoencephalopathy. His top areas of expertise are T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Multiple Myeloma, Bone Marrow Aspiration, and Bone Marrow Transplant.

His clinical research consists of co-authoring 100 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 3 articles in the study of Progressive Multifocal Leukoencephalopathy.

Graduate Institution
University Of Southern California Keck School Of Medicine, 2000
Residency
Duke University Hospital
Specialties
Hematology
Oncology
Licenses
Internal Medicine in MO
Board Certifications
American Board Of Internal Medicine - Hematology (Certified)
Hospital Affiliations
Northwestern Memorial Hospital
Northwestern Medicine Central Dupage Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Network Health
  • HMO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

675 N St Clair St Ste 21-100, Galter Pavilion, Chicago, IL 60611

Additional Areas of Focus

Dr. Carson has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Tempus Small Cell Lung Cancer Observational Study (Sculptor): A Tissue and Longitudinal Circulating Tumor DNA (ctDNA) Biomarker Profiling Study of Patients With Small Cell Lung Cancer (SCLC) Using Comprehensive Next-Generation Sequencing (NGS) Assays
Tempus Small Cell Lung Cancer Observational Study (Sculptor): A Tissue and Longitudinal Circulating Tumor DNA (ctDNA) Biomarker Profiling Study of Patients With Small Cell Lung Cancer (SCLC) Using Comprehensive Next-Generation Sequencing (NGS) Assays
Enrollment Status: Recruiting
Publish Date: May 06, 2025
Intervention Type: Other
Effect of Vitamin D Replacement on Tumor Response and Survival Parameters for Vitamin D Insufficient Patients With Cancer
Effect of Vitamin D Replacement on Tumor Response and Survival Parameters for Vitamin D Insufficient Patients With Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 13, 2025
Intervention Type: Dietary supplement, Other
Study Drug: Cholecalciferol
Study Phase: Not Applicable
Tempus Priority Study: An Observational Study of Patients Who Have Received Comprehensive Genomic Profiling
Tempus Priority Study: An Observational Study of Patients Who Have Received Comprehensive Genomic Profiling
Enrollment Status: Active_not_recruiting
Publish Date: May 06, 2025
Intervention Type: Other
The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study
The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study
Enrollment Status: Withdrawn
Publish Date: June 22, 2023
A Phase I Trial of Brentuximab Vedotin in Combination With Lenalidomide in Relapsed or Refractory Diffuse Large B-cell Lymphoma
A Phase I Trial of Brentuximab Vedotin in Combination With Lenalidomide in Relapsed or Refractory Diffuse Large B-cell Lymphoma
Enrollment Status: Completed
Publish Date: February 17, 2022
Intervention Type: Drug
Study Drugs: Brentuximab vedotin, Lenalidomide
Study Phase: Phase 1
A Phase I/II Study of X-82, an Oral Anti-VEGFR Tyrosine Kinase Inhibitor, With Everolimus for Patients With Pancreatic Neuroendocrine Tumors
A Phase I/II Study of X-82, an Oral Anti-VEGFR Tyrosine Kinase Inhibitor, With Everolimus for Patients With Pancreatic Neuroendocrine Tumors
Enrollment Status: Terminated
Publish Date: July 08, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Blinded, Prospective Non-Interventional Observational Study for the Evaluation of a GVHD Negative Outcome Score (GNOS) in Matched Unrelated or Haploidentical Hematopoietic Stem Cell Transplant
A Blinded, Prospective Non-Interventional Observational Study for the Evaluation of a GVHD Negative Outcome Score (GNOS) in Matched Unrelated or Haploidentical Hematopoietic Stem Cell Transplant
Enrollment Status: Completed
Publish Date: February 04, 2021
A Multicenter Phase I Dose-finding and Preliminary Efficacy Study of the Histone Deacetylase Inhibitor Romidepsin (Istodax) in Combination With Gemcitabine (Gemzar), Oxaliplatin (Eloxatin), and Dexamethasone for the Treatment of Adults With Relapsed/Refractory Aggressive Lymphomas
A Multicenter Phase I Dose-finding and Preliminary Efficacy Study of the Histone Deacetylase Inhibitor Romidepsin (Istodax) in Combination With Gemcitabine (Gemzar), Oxaliplatin (Eloxatin), and Dexamethasone for the Treatment of Adults With Relapsed/Refractory Aggressive Lymphomas
Enrollment Status: Completed
Publish Date: November 17, 2020
Intervention Type: Drug
Study Phase: Phase 1
Prospective Collection of Data in Pts With Peripheral T-Cell Lymphoma: PTCL,NOS;AITL; Extranodal NK/T-cell;Enteropathy-type; Hepatosplenic γ-δ; Subcutaneous Panniculitis-like; ALCL,Primary Systemic Type. By the Intl. T-Cell Lymphoma Project
Prospective Collection of Data in Pts With Peripheral T-Cell Lymphoma: PTCL,NOS;AITL; Extranodal NK/T-cell;Enteropathy-type; Hepatosplenic γ-δ; Subcutaneous Panniculitis-like; ALCL,Primary Systemic Type. By the Intl. T-Cell Lymphoma Project
Enrollment Status: Completed
Publish Date: July 08, 2019
View 8 Less Clinical Trials

100 Total Publications

Cancer Drugs and United States Tariffs: Attention Must Be Paid.
Cancer Drugs and United States Tariffs: Attention Must Be Paid.
Journal: Cancer journal (Sudbury, Mass.)
Published: May 29, 2025
Similar Doctors
Distinguished in Progressive Multifocal Leukoencephalopathy
Dr. Charles L. Bennett
Oncology
Distinguished in Progressive Multifocal Leukoencephalopathy
Dr. Charles L. Bennett
Oncology
675 N Saint Clair St, Galter 21-100, 
Chicago, IL 
 (0.4 miles away)
312-695-6180
Languages Spoken:
English

Charles Bennett is an Oncologist in Chicago, Illinois. Dr. Bennett is rated as an Advanced provider by MediFind in the treatment of Progressive Multifocal Leukoencephalopathy. His top areas of expertise are Progressive Multifocal Leukoencephalopathy, Prostate Cancer, Agranulocytosis, Prostatectomy, and Colonoscopy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Carson's expertise for a condition
ConditionClose
    View All 11 Advanced Conditions
    View All 25 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile